Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Sponsor
The First Affiliated Hospital of Anhui Medical University
Study ID
NCT03224221
Phase
PHASE2
Status
Unknown

Conditions

  • Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
  • fluorouracil and platinum — DRUG
    the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients

Study Details

We conduct the clinical trial to further explore the efficacy and safety of Apatinib combined with chemotherapy in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.

Key Dates

Start date
Mar 23, 2017
Status verified
Jun 2017
Primary completion
Jan 23, 2019
Completion
Jun 23, 2019

Study Design

Enrollment
189 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib with Chemotherapy
    Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
  • Active Comparator: Chemotherapy
    Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.

Primary Outcome Measure

One-year survival rate [ Time Frame: 12 months ]

Central Contacts

Related Studies